Tech Company Financing Transactions
Dicerna Pharmaceuticals Funding Round
On 10/22/2010, Dicerna Pharmaceuticals announced $4 million in Series B funding from SR One Capital Management.
Transaction Overview
Company Name
Announced On
10/22/2010
Transaction Type
Venture Equity
Amount
$4,000,000
Round
Series B
Investors
SR One Capital Management (Brian Gallagher)
Proceeds Purpose
Proceeds from the Series B financing will be used to advance Dicerna's lead in-house program in oncology towards clinical development and progress its other preclinical programs. The company also plans to use the proceeds to continue to develop its delivery technologies, including its proprietary lipid nanoparticle system and novel lipid platform, and targeted delivery systems which combine Dicerna's DsiRNA molecules with targeting moieties such as peptides, aptamers or antibodies.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
33 Hayden Ave.
Lexington, MA 02421
USA
Lexington, MA 02421
USA
Phone
Website
Email Address
Overview
Dicerna (NASDAQ: DRNA) is working to improve the lives of people suffering from rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. We discover and develop innovative therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 10/22/2010: GigaOmniMedia venture capital transaction
Next: 10/22/2010: rPath venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records on this site are derived from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs